Healthy volunteers to test higher doses of experimental liver drug
NCT ID NCT07262346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a higher dose of Hydronidone capsules in 138 healthy Chinese adults to see how the drug moves through the body and if it is safe. Participants will receive single or multiple doses, and some will take the drug with food to see if meals affect absorption. The results will help plan future studies for liver fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can extra doses of an old drug reverse liver scarring?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Food flavors on the breath may reveal hidden liver disease